Across TCGA pan-cancer cohorts, GPR20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPR20 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GPR20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR20 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCEC, GBM, and PRAD are the cancer types where GPR20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.058	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	5	view →
SKCM	DFS	Median	II,III,IV	0.762	0.267	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GPR20 tumor-vs-normal RNA expression · all GPR20 data types